Bacterial efflux pump inhibitors from natural sources
Open Access
- 4 December 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 59 (6), 1247-1260
- https://doi.org/10.1093/jac/dkl460
Abstract
The rapid spread of bacteria expressing multidrug resistance (MDR) has necessitated the discovery of new antibacterials and resistance-modifying agents. Since the initial discovery of bacterial efflux pumps in the 1980s, many have been characterized in community- and hospital-acquired Gram-positive and Gram-negative pathogens, such as Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli and, more recently, in mycobacteria. Efflux pumps are able to extrude structurally diverse compounds, including antibiotics used in a clinical setting; the latter are rendered therapeutically ineffective. Antibiotic resistance can develop rapidly through changes in the expression of efflux pumps, including changes to some antibiotics considered to be drugs of last resort. It is therefore imperative that new antibiotics, resistance-modifying agents and, more specifically, efflux pump inhibitors (EPIs) are characterized. The use of bacterial resistance modifiers such as EPIs could facilitate the re-introduction of therapeutically ineffective antibiotics back into clinical use such as ciprofloxacin and might even suppress the emergence of MDR strains. Here we review the literature on bacterial EPIs derived from natural sources, primarily those from plants. The resistance-modifying activities of many new chemical classes of EPIs warrant further studies to assess their potential as leads for clinical development.Keywords
This publication has 92 references indexed in Scilit:
- Mechanisms of bacterial biocide and antibiotic resistanceJournal of Applied Microbiology, 2002
- Linezolid resistance in a clinical isolate of Staphylococcus aureusThe Lancet, 2001
- Vancomycin-Resistant EnterococciClinical Microbiology Reviews, 2000
- The threat of vancomycin resistanceThe American Journal of Medicine, 1999
- Staphylococcus aureuswith Reduced Susceptibility to Vancomycin Isolated from a Patient with Fatal BacteremiaEmerging Infectious Diseases, 1999
- Ciprofloxacin Resistance among Nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United StatesInfection Control & Hospital Epidemiology, 1995
- Prevention of Drug Access to Bacterial Targets: Permeability Barriers and Active EffluxScience, 1994
- Emergence of quinolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Ontario, CanadaAntimicrobial Agents and Chemotherapy, 1991
- Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modificationAntimicrobial Agents and Chemotherapy, 1991
- Rapid Development of Ciprofloxacin Resistance in Methicillin-Susceptible and -Resistant Staphylococcus aureusThe Journal of Infectious Diseases, 1991